Analytical considerations and clinical utility of plasma phosphorylated Tau217.

IF 5.5 2区医学 Q1 MEDICAL LABORATORY TECHNOLOGY

Critical reviews in clinical laboratory sciences Pub Date : 2025-09-15 DOI:10.1080/10408363.2025.2551648

Hans Frykman

{"title":"Analytical considerations and clinical utility of plasma phosphorylated Tau217.","authors":"Hans Frykman","doi":"10.1080/10408363.2025.2551648","DOIUrl":null,"url":null,"abstract":"<p><p>Blood-based biomarkers are an easily available and practical tool for Alzheimer's disease (AD) screening and diagnosis. Plasma phosphorylated Tau217 (p-tau217) is the front-runner candidate for AD diagnosis due to its strong correlation with core AD pathology determined either by cerebrospinal fluid biomarker (CSF) and positron emission tomography (PET) or postmortem examination. While plasma p-tau217 is firmly associated with AD pathology, it is crucial to evaluate its performance in distinguishing AD from mixed pathologies, as brain autopsies have shown the coexisting of AD pathology with other related types of dementia. Moreover, the measurement of AD biomarkers will be a crucial element in defining eligibility for disease-modifying treatment in clinical practice. Moreover, plasma p-tau217 is a highly efficacious biomarker in the early detection of Aβ pathology, making it a feasible test for AD screening in clinical practice. Several assays, including the ALZpath p-tau217 assay and the Fujirebio plasma p-tau217 assay, have been made commercially available for research use. A few studies analytically and clinically have validated these immunoassays as laboratory diagnostic tests for AD diagnosis and differentiating from non-AD neurodegenerative disorders in clinical practice.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":" ","pages":"1-11"},"PeriodicalIF":5.5000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in clinical laboratory sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10408363.2025.2551648","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Blood-based biomarkers are an easily available and practical tool for Alzheimer's disease (AD) screening and diagnosis. Plasma phosphorylated Tau217 (p-tau217) is the front-runner candidate for AD diagnosis due to its strong correlation with core AD pathology determined either by cerebrospinal fluid biomarker (CSF) and positron emission tomography (PET) or postmortem examination. While plasma p-tau217 is firmly associated with AD pathology, it is crucial to evaluate its performance in distinguishing AD from mixed pathologies, as brain autopsies have shown the coexisting of AD pathology with other related types of dementia. Moreover, the measurement of AD biomarkers will be a crucial element in defining eligibility for disease-modifying treatment in clinical practice. Moreover, plasma p-tau217 is a highly efficacious biomarker in the early detection of Aβ pathology, making it a feasible test for AD screening in clinical practice. Several assays, including the ALZpath p-tau217 assay and the Fujirebio plasma p-tau217 assay, have been made commercially available for research use. A few studies analytically and clinically have validated these immunoassays as laboratory diagnostic tests for AD diagnosis and differentiating from non-AD neurodegenerative disorders in clinical practice.

查看原文本刊更多论文

血浆磷酸化Tau217的分析考虑及临床应用。

基于血液的生物标志物是阿尔茨海默病（AD）筛查和诊断的一种容易获得和实用的工具。血浆磷酸化的Tau217 （p-tau217）是阿尔茨海默病诊断的热门候选物，因为它与阿尔茨海默病的核心病理有很强的相关性，无论是通过脑脊液生物标志物（CSF）和正电子发射断层扫描（PET）还是死后检查。虽然血浆p-tau217与AD病理密切相关，但评估其在区分AD和混合病理方面的作用至关重要，因为脑尸检显示AD病理与其他相关类型的痴呆并存。此外，在临床实践中，AD生物标志物的测量将是确定疾病改善治疗资格的关键因素。此外，血浆p-tau217是一种非常有效的早期检测a β病理的生物标志物，使其在临床实践中成为阿尔茨海默病筛查的可行测试。几种检测方法，包括ALZpath p-tau217检测和Fujirebio血浆p-tau217检测，已经商业化用于研究。一些分析性和临床研究证实了这些免疫测定在临床实践中作为阿尔茨海默病诊断和与非阿尔茨海默病神经退行性疾病鉴别的实验室诊断试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Critical reviews in clinical laboratory sciences 医学-医学实验技术

CiteScore

20.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Critical Reviews in Clinical Laboratory Sciences publishes comprehensive and high quality review articles in all areas of clinical laboratory science, including clinical biochemistry, hematology, microbiology, pathology, transfusion medicine, genetics, immunology and molecular diagnostics. The reviews critically evaluate the status of current issues in the selected areas, with a focus on clinical laboratory diagnostics and latest advances. The adjective “critical” implies a balanced synthesis of results and conclusions that are frequently contradictory and controversial.